If electroconvulsive therapy is the heavyweight of brain stimulation in psychiatry, transcranial magnetic stimulation (TMS) is the lightweight challenger that keeps showing up in the data. It is non-invasive, requires no anaesthesia, and patients drive themselves home afterwards. It is FDA-cleared for major depression, OCD, smoking cessation, and migraine — but in schizophrenia, the picture is messier.
TMS is not FDA-approved for schizophrenia, but a meaningful body of research suggests it can reduce treatment-resistant auditory hallucinations and modestly improve negative symptoms in some patients.
What TMS does
A pulsed magnetic field is delivered through a coil held against the scalp. The field induces small electrical currents in the cortex directly underneath, modulating activity in that brain region. Repetitive TMS (rTMS) delivers trains of pulses — high-frequency rTMS tends to increase cortical excitability, low-frequency rTMS tends to decrease it. A newer variant, theta-burst stimulation (TBS), achieves similar effects in much shorter sessions.
A typical course is 20 to 30 sessions over 4 to 6 weeks. Each session lasts 20 to 40 minutes. Most patients describe it as a tapping sensation on the scalp.
The two schizophrenia targets that have been most studied
1. Persistent auditory hallucinations
The hypothesis: voices are linked to overactivity in the left temporoparietal cortex (a language-processing region). Low-frequency rTMS to this area has been studied extensively. Several meta-analyses, including work published in Schizophrenia Bulletin, suggest a modest but real reduction in voice severity for a subset of patients with treatment-resistant auditory hallucinations. Effect sizes are smaller than for depression with TMS, and not every trial has been positive.
This is currently the most evidence-supported brain-stimulation use in schizophrenia outside of ECT.
2. Negative symptoms
The hypothesis: negative symptoms (apathy, flat affect, reduced motivation) are linked to reduced activity in the dorsolateral prefrontal cortex. High-frequency rTMS to this region has been tried in dozens of small trials. Results are inconsistent — some show modest improvement in negative symptoms, others show no benefit. The 2020 PSYRATS-N analysis and subsequent reviews are cautious but not dismissive.
If you see a clinic advertising TMS as an established treatment for negative symptoms in schizophrenia, the marketing is ahead of the evidence.
What about cognitive symptoms?
A handful of small trials have looked at TMS for cognitive symptoms (working memory, attention) in schizophrenia. Results are preliminary at best. This is an area of active research, not clinical practice.
Side effects and safety
TMS is well tolerated. The most common side effects are:
- Scalp discomfort during stimulation
- Headache, usually mild and short-lived
- Brief jaw or facial muscle twitching
The serious risk is seizure, which is rare (roughly 1 per 30,000 sessions with appropriate screening). People with a history of seizures, metal implants near the head, or certain neurological conditions may not be candidates.
How it compares to ECT
TMS is not as powerful as ECT and not a substitute for it. ECT remains the procedure of choice for catatonia, severe acute psychosis where rapid response is needed, and as clozapine augmentation. TMS may have a role for stable patients with persistent voices despite adequate medication, but the responder rate is lower and the effect more modest.
The major advantage of TMS: no anaesthesia, no cognitive side effects, no recovery time. The major disadvantage: smaller effect sizes and a less established schizophrenia evidence base.
What insurance and access look like
In the US, most insurers cover TMS only for FDA-approved indications (depression, OCD). Off-label use for schizophrenia is generally not covered, which puts it out of reach for many patients without research-trial enrolment. Some academic centres run schizophrenia-specific TMS programmes; the National Institute of Mental Health maintains a clinical trial finder at nimh.nih.gov/health/trials.
Reasonable questions if it's being suggested
- What is the specific target — voices, negative symptoms, depression, something else?
- What protocol (frequency, location, number of sessions)?
- Is this within a clinical trial, an off-label clinic offering, or part of insurance-covered depression treatment?
- What does the responder rate look like for this specific use?
- What is the plan if it doesn't help?
Standalone TMS clinics sometimes market the service for nearly any psychiatric condition. For schizophrenia specifically, ask hard questions about evidence and don't expect insurance coverage outside FDA indications.
What this means for most patients
For someone newly diagnosed with schizophrenia, TMS is not on the standard treatment ladder. The sequence is medication, therapy, lifestyle, and — if needed — clozapine and ECT. TMS becomes a reasonable conversation when persistent voices remain despite adequate medication trials, when clozapine is not an option or has not fully worked, and when the patient prefers a non-invasive intervention.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.